Clinical Trial Update: Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for a vaccine therapy in high-risk Stage III or completely resected metastatic melanoma shows completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Melanoma, Stage III Melanoma | Phase 2 | Status: COMPLETED